Avoid common mistakes on your manuscript.
Erratum to: Ann Hematol (1997) 75:135–140
DOI 10.1007/s002770050330
The original version of this article inadvertently contained a mistake. In Fig. 4, overall survival the labels were mixed up. The label for the solid line must be changed to CEOP/IMVP-Dexa+filgrastim, and for the dotted line to CEOP/IMVP-Dexa.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s002770050330.
Rights and permissions
About this article
Cite this article
Fridrik, M.A., Greil, R., Hausmaninger, H. et al. Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy. Ann Hematol 93, 539–540 (2014). https://doi.org/10.1007/s00277-013-1983-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-013-1983-y